Published in FASEB J on August 01, 2003
The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology (2008) 1.79
A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res (2006) 1.57
Ca(2+) -stimulated basal adenylyl cyclase activity localization in membrane lipid microdomains of cardiac sinoatrial nodal pacemaker cells. J Biol Chem (2008) 1.40
Natriuretic peptide C receptor signalling in the heart and vasculature. J Physiol (2007) 1.26
Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin (2008) 0.99
Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res (2012) 0.95
Cyclic nucleotide specific phosphodiesterases of Leishmania major. BMC Microbiol (2006) 0.93
Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression. Learn Mem (2008) 0.90
Molecular targets in heart failure gene therapy: current controversies and translational perspectives. Ann N Y Acad Sci (2012) 0.89
A compartmentalized mathematical model of the β1-adrenergic signaling system in mouse ventricular myocytes. PLoS One (2014) 0.75
Ca(2+)/calmodulin-activated phosphodiesterase 1A is highly expressed in rabbit cardiac sinoatrial nodal cells and regulates pacemaker function. J Mol Cell Cardiol (2016) 0.75
Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res (2006) 2.59
Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg Med Chem (2002) 2.03
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation (2006) 1.96
The cAMP binding protein Epac modulates Ca2+ sparks by a Ca2+/calmodulin kinase signalling pathway in rat cardiac myocytes. J Physiol (2007) 1.85
Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload. Cardiovasc Res (2012) 1.79
Mouse bestrophin-2 is a bona fide Cl(-) channel: identification of a residue important in anion binding and conduction. J Gen Physiol (2004) 1.79
Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol (2013) 1.68
Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation (2004) 1.67
cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ Res (2005) 1.66
A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res (2006) 1.57
Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res (2008) 1.50
Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res (2003) 1.49
Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat Cell Biol (2003) 1.46
Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res (2010) 1.41
Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem (2004) 1.33
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol (2012) 1.26
Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol (2005) 1.22
Mitochondrial uncoupling protein 1 expressed in the heart of transgenic mice protects against ischemic-reperfusion damage. Circulation (2004) 1.21
Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice. J Physiol (2007) 1.19
Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J Clin Invest (2008) 1.19
SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther (2010) 1.18
Hepatitis C virus (HCV) protein expression enhances hepatic fibrosis in HCV transgenic mice exposed to a fibrogenic agent. J Hepatol (2012) 1.17
PDEs create local domains of cAMP signaling. J Mol Cell Cardiol (2011) 1.16
31P NMR detection of subcellular creatine kinase fluxes in the perfused rat heart: contractility modifies energy transfer pathways. J Biol Chem (2002) 1.15
Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One (2011) 1.13
Functional expression of the hyperpolarization-activated, non-selective cation current I(f) in immortalized HL-1 cardiomyocytes. J Physiol (2002) 1.13
Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias. J Am Coll Cardiol (2012) 1.12
Real-time assessment of myocardial contractility using shear wave imaging. J Am Coll Cardiol (2011) 1.10
Phosphodiesterase 4B in the cardiac L-type Ca²⁺ channel complex regulates Ca²⁺ current and protects against ventricular arrhythmias in mice. J Clin Invest (2011) 1.09
Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa,L in frog ventricular myocytes. J Physiol (2003) 1.05
Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol (2006) 1.04
Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ Res (2009) 1.03
beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest (2008) 1.01
Modulation of energy transfer pathways between mitochondria and myofibrils by changes in performance of perfused heart. J Biol Chem (2010) 1.01
Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun (2002) 1.01
5-HT4 receptor ligands: applications and new prospects. J Med Chem (2003) 1.00
Impaired voluntary running capacity of creatine kinase-deficient mice. J Physiol (2005) 1.00
Constitutive dimerization of human serotonin 5-HT4 receptors in living cells. FEBS Lett (2005) 1.00
Dual cardiac contractile effects of the alpha2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2007) 0.99
Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J Biol Chem (2012) 0.98
An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart. Cardiovasc Res (2013) 0.98
High level of uncoupling protein 1 expression in muscle of transgenic mice selectively affects muscles at rest and decreases their IIb fiber content. J Biol Chem (2002) 0.97
AMP-activated protein kinase alpha2 deficiency affects cardiac cardiolipin homeostasis and mitochondrial function. Diabetes (2007) 0.97
A new regulation of IL-6 production in adult cardiomyocytes by beta-adrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling. Cell Signal (2010) 0.97
VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost (2003) 0.96
The cardiac beta2-adrenergic signalling a new role for the cPLA2. Cell Signal (2005) 0.95
Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res (2011) 0.95
SERCA2a controls the mode of agonist-induced intracellular Ca2+ signal, transcription factor NFAT and proliferation in human vascular smooth muscle cells. J Mol Cell Cardiol (2010) 0.95
Decreased sarcolipin protein expression and enhanced sarco(endo)plasmic reticulum Ca2+ uptake in human atrial fibrillation. Biochem Biophys Res Commun (2011) 0.94
Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. Planta Med (2005) 0.94
Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. J Mol Cell Cardiol (2007) 0.93
Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des (2010) 0.92
Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol (2009) 0.92
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors. J Med Chem (2012) 0.92
Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost (2004) 0.92
Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis. Cardiovasc Res (2003) 0.91
Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. Br J Pharmacol (2006) 0.91
Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation (2012) 0.91
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS One (2010) 0.90
Molecular targets in heart failure gene therapy: current controversies and translational perspectives. Ann N Y Acad Sci (2012) 0.89
Cyclic AMP synthesis and hydrolysis in the normal and failing heart. Pflugers Arch (2014) 0.89
Post-translational modifications of cardiac tubulin during chronic heart failure in the rat. Mol Cell Biochem (2002) 0.89
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther (2002) 0.88
Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. J Clin Endocrinol Metab (2012) 0.88
Cardiovascular effects of Urtica dioica L. in isolated rat heart and aorta. Phytother Res (2002) 0.88
Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
Regulation of the amyloid precursor protein ectodomain shedding by the 5-HT4 receptor and Epac. FEBS Lett (2005) 0.87
NO donors potentiate the beta-adrenergic stimulation of I(Ca,L) and the muscarinic activation of I(K,ACh) in rat cardiac myocytes. J Physiol (2002) 0.87
Augmentation of cardiac contractility with no change in L-type Ca2+ current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J (2002) 0.86
Two transmembrane Cys residues are involved in 5-HT4 receptor dimerization. Biochem Biophys Res Commun (2007) 0.86
The cytosolic phospholipase A2 pathway, a safeguard of beta2-adrenergic cardiac effects in rat. J Biol Chem (2005) 0.85
Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol Biol (2005) 0.85
Transcription of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase type 3 gene, ATP2A3, is regulated by the calcineurin/NFAT pathway in endothelial cells. Biochem J (2006) 0.85